SpeeDx | GenomeWeb

SpeeDx

As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.

The firm plans to submit the Mycoplasma genitalium test to the FDA in 2017 and has entered an agreement with the CDC for test evaluation. 

The multiplex qPCR test can detect and discriminate herpes simplex virus 1 and 2 as well as varicella zoster virus, which can be mistaken for HSV in a proportion of cases.

The antibiotic-resistant Mycoplasma genitalium test would be the first on the market for a pathogen with increasing evidence for adverse outcomes.

Under the agreement, Goffin will distribute SpeeDx's PlexPCR and ResistancePlus multiplex real-time PCR product lines in Benelux.

The Australian firm provided an update on its in vitro diagnostics business, noting that it has also rebranded its core technologies and continues to license them.

Trends included expanding test menus and a possible tipping point for point-of-care.

After receiving ISO certification and publishing studies on its technology in 2014, the Australian MDx firm is targeting a launch of its meningitis test in 2015.

SpeeDx of Eveleigh, Australia, has been awarded US Patent No. 8,394,946, "Multicomponent nucleic acid enzymes and methods for their use."
Alison Todd, Donald Birkett, Tram Doan, and Elisa Mokany are named as inventors.

Australian molecular diagnostics and research tools firm SpeeDx has published research demonstrating how its proprietary class of nucleic acid enzymes, called MNAzymes, can be used in combination with standard qPCR reagents to enable easy, inexpensive development of highly sensit

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.